版本:
中国

BRIEF-Mabvax Therapeutics reports positive phase 1 results for MVT-2163 immunopet imaging agent

June 14 Mabvax Therapeutics Holdings Inc

* Mabvax Therapeutics reports positive phase 1 results for mvt-2163 immunopet imaging agent

* Mabvax therapeutics holdings inc - mvt-2163 immunopet agent administered in combination with mvt-5873 was safe and well tolerated

* Mabvax Therapeutics holdings inc - "anticipate initiating patient dosing of our mvt-1075 radioimmunotherapy trial later this month"

* Mabvax Therapeutics - for mvt-2163, only toxicities were infusion reactions that resolved on day of injection, with some requiring supportive medication

* Mabvax Therapeutics holdings inc - results showed that mvt-5873 cold antibody pre-dose reduces liver suv facilitating detection of liver metastases

* Mabvax Therapeutics holdings inc - in addition, mvt-5873 cold antibody pre-dose does not interfere with uptake of mvt-2163 on cancer lesions Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐